| Not Yet Recruiting | Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) NCT07016321 | Johns Hopkins University | Phase 2 / Phase 3 |
| Not Yet Recruiting | Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikung NCT06973772 | Butantan Institute | Phase 3 |
| Completed | Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities NCT07517731 | University of Freiburg | N/A |
| Active Not Recruiting | Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam NCT07501793 | Tam Anh Research Institute | — |
| Recruiting | Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) NCT06891950 | Butantan Institute | Phase 3 |
| Recruiting | A Controlled Human Infection Model of Dengue NCT07412483 | Tan Tock Seng Hospital | N/A |
| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Not Yet Recruiting | Dengue - Sample Collection Study Pakistan NCT07203183 | Abbott Rapid Dx | — |
| Not Yet Recruiting | Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immu NCT06908018 | Mahidol University | EARLY_Phase 1 |
| Not Yet Recruiting | Adaptive Dengue Antiviral Platform Trial NCT06551844 | Oxford University Clinical Research Unit, Vietnam | Phase 2 |
| Recruiting | Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection NCT07007585 | Jose Ivan Rodriguez de Molina Serrano | — |
| Not Yet Recruiting | Effectiveness Evaluation of the "Mosquito-Free Campus" Initiative on Dengue Fever Prevention and Control: A Cl NCT07002021 | Sun Yat-sen University | N/A |
| Recruiting | Immune Responses to Dengue and Sepsis NCT07040202 | Institut Pasteur du Cambodge | — |
| Completed | Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers NCT06837116 | Prince of Songkla University | EARLY_Phase 1 |
| Recruiting | Impact of IIT-SIT on Dengue Clusters NCT06894901 | National Environment Agency, Singapore | N/A |
| Recruiting | Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients NCT06747130 | Phramongkutklao College of Medicine and Hospital | Phase 2 / Phase 3 |
| Completed | Study to Examine the Effects of Oral Fenretinide NCT06528457 | Island Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda). NCT07158190 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility NCT06599970 | Institute of Tropical Medicine, Belgium | — |
| Terminated | Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale NCT06595745 | Michigan State University | N/A |
| Recruiting | A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever NCT06006559 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Dengue Virus Infection Amongst Patients With Acute Febrile Illness NCT06255509 | Tangerang District Hospital | — |
| Completed | Homologous Re-infection With Dengue 1 or Dengue 3 NCT05967455 | State University of New York - Upstate Medical University | Phase 1 |
| Completed | Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial NCT06121934 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 3 |
| Unknown | A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires NCT05919277 | Fundacion GESICA | — |
| Completed | Educational Intervention to Promote Control Behaviors and Prevention of Dengue NCT05321264 | Universidad de Antioquia | N/A |
| Completed | Citizen Action for Sustainable Dengue Control in Sub-Saharan Africa NCT06648603 | Swiss Tropical & Public Health Institute | N/A |
| Not Yet Recruiting | Study of Dengue in Patients With Autoimmune Diseases During the Epidemics of 2020 and 2021 in Reunion Island NCT05852977 | Centre Hospitalier Universitaire de la Réunion | — |
| Completed | Identification of Risk Determinants of Dengue Transmission Through Landscape Analysis NCT05893134 | Instituto Mexicano del Seguro Social | — |
| Completed | Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and A NCT06257810 | BioMérieux | N/A |
| Terminated | A Study of JNJ-64281802 for the Prevention of Dengue Infection NCT05201794 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Den NCT05710224 | Butantan Institute | Phase 2 |
| Completed | Effectiveness Evaluation of a Dengue Self-monitoring System NCT05688748 | University of Malaya | N/A |
| Active Not Recruiting | Anakinra in Dengue With Hyperinflammation ( AnaDen ) NCT05611710 | Oxford University Clinical Research Unit, Vietnam | Phase 2 |
| Unknown | Effectiveness of a Online Education Material to Improve Dengue Knowledge and Health-Seeking Intention NCT05661877 | University of Malaya | N/A |
| Completed | Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu NCT05153018 | Institut Pasteur | N/A |
| Unknown | Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169. NCT05476757 | Mahidol University | EARLY_Phase 1 |
| Completed | Impact of Project Wolbachia - Singapore on Dengue Incidence NCT05505682 | National Environment Agency, Singapore | N/A |
| Unknown | Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in M NCT04947111 | Mexican Society of Public Health | N/A |
| Terminated | Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model NCT05366439 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Dengue Vaccine Hesitancy and Acceptance in Endemic Regions of Argentina: Impact of Communication Strategies NCT05213364 | Fundacion GESICA | — |
| Completed | Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4) NCT05268302 | University of Maryland, Baltimore | Phase 1 |
| Completed | An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge NCT05048875 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever NCT04906980 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | Dengue Controlled Human Infection Model in Dhaka, Bangladesh NCT05229354 | Beth Kirkpatrick | Phase 2 |
| Completed | A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus NCT04935801 | Gylden Pharma Ltd | Phase 1 |
| Unknown | Study on the Risks of Symptomatic Dengue on Pregnancy NCT04826081 | Centre Hospitalier Universitaire de la Réunion | — |
| Recruiting | Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean NCT04839757 | University Hospital Center of Martinique | — |
| Unknown | Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal NCT05050825 | Foundation for Innovative New Diagnostics, Switzerland | N/A |
| Completed | Study of AT-752 in Healthy Subjects NCT04722627 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Completed | Effects of a Serious Game on Knowledge, Attitude and Practice in Vector Control and Dengue Prevention Among Ad NCT05307484 | SingHealth Polyclinics | N/A |
| Recruiting | Virological and Immunological Determinants of Arbovirus Infection in New Caledonia NCT04619823 | Institut Pasteur | N/A |
| Unknown | Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Fo NCT04672577 | Patricia Schlagenhauf | — |
| Completed | Characterizing Humoral Immune Response to Mosquito Bites NCT04478370 | University of Oxford | N/A |
| Completed | Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients NCT04673422 | Phramongkutklao College of Medicine and Hospital | Phase 2 / Phase 3 |
| Completed | ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) NCT04786457 | University of Maryland, Baltimore | Phase 1 |
| Completed | Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases NCT04343521 | Emory University | N/A |
| Unknown | Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso NCT04582474 | Foundation for Innovative New Diagnostics, Switzerland | N/A |
| Completed | Dengue 3 Human Infection Model (DENV-3) NCT04298138 | State University of New York - Upstate Medical University | Phase 1 |
| Completed | Metformin in Dengue With Obesity NCT04377451 | Oxford University Clinical Research Unit, Vietnam | Phase 1 / Phase 2 |
| Recruiting | Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia NCT04615364 | Institut Pasteur | — |
| Completed | Safety Study of Dengushield in Healthy Adults NCT03883620 | Serum Institute of India Pvt. Ltd. | Phase 1 |
| Completed | Expansion of a Dengue-1 Live Virus Human Challenge NCT03869060 | State University of New York - Upstate Medical University | Phase 1 |
| Completed | Pilot Study to Detect DENGUE Virus in Sperm NCT03612609 | University Hospital, Toulouse | N/A |
| Completed | Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating NCT06268691 | Rocio Cardenas Sanchez | N/A |
| Completed | Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the E NCT04133987 | National Taiwan University Hospital | Phase 2 |
| Unknown | Combating Dengue With Innovative, Paradigm-shift-Strategies: Early Dengue Surveillance in Adult Aedes Mosquito NCT03799237 | Jonathan Liew Wee Kent | N/A |
| Completed | Defining Skin Immunity of a Bite of Key Insect Vectors in Humans NCT03641339 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | Bedside Ultrasound Predicts Progression of Severity of Disease in Dengue Fever NCT03632486 | Timothy Gleeson | — |
| Completed | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adul NCT03342898 | Takeda | Phase 3 |
| Completed | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) NCT03341637 | Takeda | Phase 3 |
| Completed | A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan NCT03485144 | Medigen Vaccine Biologics Corp. | Phase 2 |
| Completed | Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challen NCT03416036 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Terminated | Applying Wolbachia to Eliminate Dengue NCT03055585 | Gadjah Mada University | N/A |
| Completed | Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia NCT03631719 | Universidad de Antioquia | — |
| Completed | Dengue Effectiveness Study in the Philippines NCT03803618 | University of the Philippines | — |
| Completed | Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptom NCT03960385 | Albert B. Sabin Vaccine Institute | — |
| Completed | Clinical Trial of Diagnostic Tests and Clinical Algorithms for Dengue in Febrile Subjects in Endemic Areas in NCT04063774 | Lyda Osorio | N/A |
| Unknown | Dengue Serostatus Study in the Philippines NCT03465254 | University of the Philippines | — |
| Completed | Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults NCT02833584 | Phramongkutklao College of Medicine and Hospital | N/A |
| Completed | Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vacci NCT02873260 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Terminated | This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months NCT02766088 | GlaxoSmithKline | N/A |
| Completed | The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico NCT02831699 | Mexican Emerging Infectious Diseases Clinical Research Network | — |
| Completed | A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in D NCT02570152 | GlaxoSmithKline | N/A |
| Completed | Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents NCT02678455 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine NCT02406729 | Butantan Institute | Phase 3 |
| Completed | Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Nai NCT02879266 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant NCT03110952 | U.S. Army Medical Research and Development Command | Phase 1 |
| Terminated | Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis NCT02435615 | University of Miami | N/A |
| Unknown | Prevalence of Hyponatremia in Dengue Infected Patients: Relationship With Systemic Inflammation. NCT06109532 | Hospital Nacional Profesor Alejandro Posadas | — |
| Completed | Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain NCT02372175 | U.S. Army Medical Research and Development Command | Phase 1 |
| Unknown | The Use of Biomarkers in Predicting Dengue Outcome NCT02606019 | Universiti Tunku Abdul Rahman | — |
| Completed | Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine t NCT02433652 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults NCT02421367 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |
| Completed | Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adul NCT02450838 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults NCT02392325 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever NCT02134652 | University of Massachusetts, Worcester | — |
| Completed | Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults NCT02317900 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | TDENV PIV and LAV Dengue Prime-boost Strategy NCT02239614 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and C NCT02332733 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil NCT01751139 | GlaxoSmithKline | N/A |
| Completed | Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue NCT01943825 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults NCT02021968 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine NCT01696422 | Butantan Institute | Phase 2 |
| Completed | Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Effi NCT01983553 | Sanofi Pasteur, a Sanofi Company | — |
| Unknown | Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter NCT02016027 | Fr Muller Homoeopathic Medical College | Phase 1 |
| Completed | Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults NCT01931176 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS NCT01702272 | Gen-Probe, Incorporated | — |
| Completed | Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart NCT01782300 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red NCT01656174 | Gen-Probe, Incorporated | — |
| Completed | Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001) NCT01477580 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Materno-fetal Consequences of Symptomatic Dengue in Pregnant Wowen in French Guiana NCT04989673 | Centre Hospitalier de Cayenne | — |
| Terminated | Insecticidal School Uniforms for Dengue Prevention in Thailand NCT01563640 | Umeå University | N/A |
| Completed | Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India NCT01550289 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vacc NCT01488890 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine NCT01506570 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers NCT01436396 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children NCT01391819 | GlaxoSmithKline | N/A |
| Completed | Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children NCT01477671 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine NCT01436422 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers NCT01411241 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin Am NCT01374516 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia NCT01373281 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Dengue Seroprevalence Study in Blood Donors in the French West Indies NCT01104740 | Etablissement Français du Sang, Martinique | — |
| Completed | Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America NCT01187433 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine NCT01072786 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of Balapiravir in Patients With Dengue Virus Infection NCT01096576 | Hoffmann-La Roche | Phase 1 |
| Unknown | Cohort of Patients Infected by an Arbovirus NCT01099852 | University Hospital Center of Martinique | — |
| Completed | Tetravalent Chimeric Dengue Vaccine Trial NCT01110551 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin NCT00993447 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Unknown | Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR NCT00938379 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults NCT00712803 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | The Effect of Chloroquine in the Treatment of Patients With Dengue NCT00849602 | University of Sao Paulo | Phase 1 / Phase 2 |
| Withdrawn | Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Vir NCT00629356 | Kaohsiung Medical University Chung-Ho Memorial Hospital | — |
| Completed | Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine NCT00473135 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand NCT00370682 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults NCT00322946 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults NCT00375726 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Prospective Study of Infant Dengue NCT00377754 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects NCT00730288 | Sanofi | Phase 2 |
| Completed | Implementation Research of New Dengue Vector Control Tools NCT00883441 | Institute of Tropical Medicine, Belgium | N/A |
| Completed | A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine i NCT00239577 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US NCT00350337 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine NCT00290147 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children NCT01843621 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |
| Completed | A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants NCT00322049 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |
| Completed | Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine NCT02684383 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |